Gragnoli G, Signorini A M, Tanganelli I
Minerva Med. 1984 Jul 31;75(30-31):1791-6.
11 insulin-dependent and 19 non insulin-dependent diabetics with varying degrees of metabolic compensation and with high plasma levels of beta-thromboglobulin and thromboxane B2 were selected. Depending on the type of diabetes and the degree of glycaemia, control plasma levels of beta-thromboglobulin and thromboxane B2 were progressively lower after 14, 28 and 42 days of treatment with ticlopidine (500 mg/per day orally), than those encountered at the start of the study. It is concluded that ticlopidine influences plasma levels of beta-thromboglobulin and thromboxane B2 independently of the type and degree of metabolic compensation in diabetes mellitus.
选取了11名胰岛素依赖型糖尿病患者和19名非胰岛素依赖型糖尿病患者,他们具有不同程度的代谢代偿,且血浆β-血小板球蛋白和血栓素B2水平较高。根据糖尿病类型和血糖水平,在用噻氯匹定(每日口服500毫克)治疗14、28和42天后,对照血浆中β-血小板球蛋白和血栓素B2的水平逐渐低于研究开始时的水平。得出的结论是,噻氯匹定对血浆β-血小板球蛋白和血栓素B2水平的影响与糖尿病的类型和代谢代偿程度无关。